Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q4 2023 Earnings Conference
Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q4 2023 Earnings Conference
The following is a summary of the Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript:
以下是Helius Medical Technologies, Inc. (HSDT) 2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Helius Medical Technologies reported a Q4 2023 revenue of $134,000, a decrease from Q4 2022's $282,000.
Cost of revenue for Q4 2023 was lower at $90,000, compared to Q4 2022's $150,000.
Operating loss was narrowed to $2.2 million in Q4 2023, from a loss of $2.7 million in Q4 2022.
Net loss was significantly decreased to $1 million in Q4 2023, down from $4.9 million in Q4 2022.
As of the end of 2023, the company had $5.2 million in cash with no debt.
Helius Medical Technologies報告稱，2023年第四季度收入爲13.4萬美元，低於2022年第四季度的28.2萬美元。
2023年第四季度的收入成本低於9萬美元，而2022年第四季度的收入成本爲15萬美元。
營業虧損從2022年第四季度的270萬美元虧損縮小至2023年第四季度的220萬美元。
淨虧損從2022年第四季度的490萬美元大幅下降至2023年第四季度的100萬美元。
截至2023年底，該公司擁有520萬澳元的現金，沒有債務。
Business Progress:
業務進展：
Helius made progress in 2023 towards securing widespread reimbursement for their PoNS device and FDA approval for stroke treatment.
Unique HCPCS codes were obtained for the PoNS controller and mouthpiece.
A program started, aiming to validate the effectiveness of PoNS Therapy for stroke patients.
Regulatory submission for the therapy is planned for early 2025.
Canadian expansion continues and 2024 is expected to bring steady progress towards overall company goals.
The company implemented a telemedicine and e-prescribing hub aiming for speedy delivery of their PoNS devices.
Partnerships were made with UpScript and neurologists for quicker online diagnoses and e-prescriptions.
Online PoNS module training for physical therapists has also been established.
Six Centers of Excellence were added for the PoNS step clinical trial in 2023.
Veteran Affairs rehab specialists have shown interest in the PoNS device due to prevalence of balance issues in veterans.
Finally, the company will work towards procuring coverage and reimbursement for PoNS therapy.
2023年，Helius在確保其PoNs設備的廣泛報銷和美國食品藥品管理局批准中風治療方面取得了進展。
獲得了 PonS 控制器和喉舌的獨特的 HCPCS 代碼。
啓動了一項計劃，旨在驗證PonS療法對中風患者的有效性。
該療法的監管申請計劃於2025年初提交。
加拿大的擴張仍在繼續，預計2024年將在實現公司總體目標方面取得穩步進展。
該公司實施了遠程醫療和電子處方中心，旨在快速交付其PoNs設備。
與UpScript和神經科醫生建立了合作伙伴關係，以更快地進行在線診斷和電子處方。
還爲物理治療師建立了在線PonS模塊培訓。
2023 年，PonS step 臨床試驗增加了六個卓越中心。
由於退伍軍人普遍存在平衡問題，退伍軍人事務康復專家對PonS設備表現出興趣。
最後，該公司將努力爲PonS療法爭取保險和報銷。
More details: Helius Medical Technologies IR
更多詳情： Helius 醫療科技 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。